BC031181 Activators are a diverse set of chemical compounds that influence the functional activity of the protein by modulating intracellular cyclic nucleotide levels, which are critical components of signaling pathways that BC031181 may be involved in. Forskolin, by directly activating adenylate cyclase, leads to increased intracellular cAMP, which could enhance BC031181 activity if it is part of the cAMP-dependent signaling pathways. Similarly, several phosphodiesterase inhibitors, including Rolipram, IBMX, and Anagrelide, contribute to elevated cAMP levels, providing a potential mechanism for the enhancement of BC031181 activity. Theophylline also functions in this capacity by non-selectively inhibiting phosphodiesterases, thus boosting cAMP levels and possibly augmenting BC031181 activity. In addition to cAMP, cGMP is another second messenger that can play a role in the activation of BC031181.
Compounds such as Zaprinast, YC-1, Sildenafil, Vardenafil, and Tadalafil act by inhibiting PDE5 or activating soluble guanylyl cyclase, leading to increased cGMP levels, which may potentiate BC031181 if it is cGMP-dependent. The modulation of cyclic nucleotide levels by these activators suggests a multifaceted approach to enhancing BC031181 activity through the fine-tuning of intracellular signaling dynamics. For instance, Milrinone and Dipyridamole, through selective and non-selective inhibition of phosphodiesterases, respectively, lead to an accumulation of cAMP, further offering a route to potentiate BC031181 if it is responsive to such signaling molecules.
SEE ALSO...
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram inhibits phosphodiesterase 4 (PDE4), leading to increased cAMP levels, potentially enhancing BC031181 activity if it is regulated by cAMP. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, leading to increased cAMP and cGMP levels, which may enhance BC031181 activity if it operates through these cyclic nucleotides. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $103.00 $245.00 | 8 | |
Zaprinast inhibits PDE5, increasing cGMP levels, which could enhance BC031181 activity if it is cGMP-dependent. | ||||||
YC-1 | 170632-47-0 | sc-202856 sc-202856A sc-202856B sc-202856C | 1 mg 5 mg 10 mg 50 mg | $32.00 $122.00 $214.00 $928.00 | 9 | |
YC-1 activates soluble guanylyl cyclase, increasing cGMP levels, which can potentiate BC031181 if it functions through cGMP signaling. | ||||||
Dipyridamole | 58-32-2 | sc-200717 sc-200717A | 1 g 5 g | $30.00 $100.00 | 1 | |
Dipyridamole is a phosphodiesterase inhibitor, which increases cAMP and cGMP levels, potentially enhancing BC031181 activity through these pathways. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $162.00 $683.00 | 7 | |
Milrinone selectively inhibits PDE3, increasing cAMP levels, and could indirectly enhance BC031181 activity if it is cAMP-mediated. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $516.00 $720.00 $16326.00 | 7 | |
Vardenafil, a PDE5 inhibitor, increases cGMP levels, which may lead to enhanced BC031181 activity if it utilizes cGMP signaling. | ||||||
Tadalafil | 171596-29-5 | sc-208412 | 50 mg | $176.00 | 13 | |
Tadalafil is a PDE5 inhibitor that elevates cGMP levels, potentially enhancing BC031181 activity if it is cGMP-dependent. | ||||||
Theophylline | 58-55-9 | sc-202835 sc-202835A sc-202835B | 5 g 25 g 100 g | $20.00 $31.00 $83.00 | 6 | |
Theophylline, by inhibiting phosphodiesterases, increases cAMP levels, which could enhance BC031181 activity if it operates through cAMP-dependent pathways. |